What are the Historical Developments and Current Growth Metrics of the Persistent Epithelial Defect Management Market?
The persistent epithelial defect management market has seen considerable growth due to a variety of factors.
• The market size for managing persistent epithelial defects has experienced swift expansion in the last few years. The expected growth is from $7.92 billion in 2024 to a projected $9.29 billion in 2025, indicating a compound annual growth rate (CAGR) of 17.3%.
The growth during the historic period was driven by increased research efforts, surging demand from hospitals, rising incidence of ocular surface disorders and eye-related ailments, coupled with an aging population.
What is the Forecasted Market Size and CAGR for the Persistent Epithelial Defect Management Market?
The persistent epithelial defect management market is expected to maintain its strong growth trajectory in upcoming years.
• The market for managing persistent epithelial defects is predicted to undergo significant expansion in the foreseeable future. It is projected to escalate to $17.35 billion by 2029, with a compound annual growth rate of 16.9%.
The predicted growth within this time frame can be traced back to the rise in partnerships and collaborations, enhanced awareness and education, a shift towards value-based care, increasing instances of diseases such as diabetes and hypertension, as well as proactive intervention and management. Key trends anticipated during this forecast period encompass technological progression, an elevated demand for novel treatment methods, developed treatment modalities, presence of sophisticated surgical tools and techniques, and innovative drug solutions.
What Key Factors and Trends Are Driving The Growth Persistent Epithelial Defect Management Market?
With the escalating occurrence of eye-related disorders, the persistent epithelial defect management market is projected to proliferate. Eye disorders, encompassing a wide spectrum of medical conditions impacting the eye's structure, function, or health, can lead to outcomes like vision impairment, discomfort, or even potential blindness. Factors propelling the prevalence of these disorders include aging populations, long durations of screen exposure, and environmental changes. Treatment of these conditions is highly reliant on persistent epithelial defect management as it instigates healing, lessens inflammation, and averts complications like infections or scarring. For example, in December 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that the pooled incidence of childhood myopia in 2023 stood at 5.23%, showing a substantially higher rate in women at 4.90% compared to men at 3.94%. Thus, the escalating incidence of eye disorders is fuelling the persistent epithelial defect management market growth. The Surge in Eye Surgeries Fueling the Market Growth
What Are The Market Segments In The Persistent Epithelial Defect Management Market?
The persistent epithelial defect management market covered in this report is segmented –
1) By Disease Type: Epithalial Or Limbal, Inflammatory Disease, Neurotrophic Disease, Other Disease Types
2) By Distribution Channel: Direct Sales, Online Pharmacy, Retail Pharmacy, Hospitals
3) By End User: Hospital Or Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users
Subsegments:
1) By Epithelial Or Limbal: Limbal Stem Cell Deficiency (LSCD), Limbal Transplantation, Conjunctival Transplantation
2) By Inflammatory Disease: Dry Eye Syndrome, Allergic Conjunctivitis, Uveitis
3) By Neurotrophic Disease: Herpes Simplex Virus (HSV) Keratitis, Diabetic Neuropathy, Neurotrophic Keratopathy
4) By Other Disease Types: Chemical Burns, Trauma-Induced Defects, Congenital Corneal Opacities
Pre-Book The Persistent Epithelial Defect Management Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Persistent Epithelial Defect Management Market?
Leading firms in the persistent epithelial defect management sector have been focusing their efforts on the creation of innovative treatment methods, such as secretome therapy, to expedite the healing process and enhance results for persistent epithelial defects. The concept behind secretome therapy involves the use of bioactive molecules secreted by cells like proteins, lipids, extracellular vesicles, to foster tissue repair, regulate immune responses, and address a variety of diseases. For example, in April 2023, a US-based biopharmaceutical firm named Kala Pharmaceuticals Inc. was awarded the U.S. Food and Drug Administration (FDA) Fast Track Designation for their product, KPI-012. This product is a human MSC-S treatment specifically designed for persistent corneal epithelial defects. By using bioactive molecules such as growth factors, protease inhibitors, and neurotrophic factors, the multifaceted mechanism of action underline in this drug aims to tackle all root causes of persistent epithelial defect management by fostering corneal healing.
Who Are the Key Players In The Persistent Epithelial Defect Management Market?
Major companies operating in the persistent epithelial defect management market are:
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson Vision
• RegeneRx Biopharmaceuticals Inc.
• Regeneron Pharmaceuticals Inc.
• Alcon Inc.
• Bausch Health Companies Inc.
• Hoya Vision Care
• Santen Pharmaceutical Co. Ltd.
• Recordati Rare Diseases Inc.
• Dompé Farmaceutici S.p.A.
• Lumenis Ltd.
• TissueTech Inc.
• Ocular Therapeutix Inc.
• Oculus Surgical Inc.
• Amber Ophthalmics Inc.
• Noveome Biotherapeutics Inc.
• OcuNexus Therapeutics Inc.
• Lux Bio Inc.
• Eyenovia Inc.
What Are The Regional Insights Into The Persistent Epithelial Defect Management Market?
North America was the largest region in the persistent epithelial defect management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the persistent epithelial defect management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
